Effects of 'NHGDoc' on Quality of Care (NHGDoc)

April 11, 2018 updated by: Radboud University Medical Center

Effects of the Computerized Decision Support System 'NHGDoc' on Quality of Care: a Cluster Randomized Controlled Trial

The purpose of this study is to determine whether the computerized decision support system 'NHGDoc' is effective in improving quality of primary care in terms of processes of care (e.g. prescribing behavior of physicians) as well as outcomes of care (e.g. hospital admissions, mortality).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Computerized decision support systems are regarded as useful tools to improve quality of care, but their effects are still uncertain. In the Netherlands 'NHGDoc' a computerized decision support system supported by the Dutch College of General Practitioners (NHG) is currently being implemented among more than 1.000 general practices in the Netherlands.

The aim of this study is to evaluate the effects of NHGDoc on quality of care. In addition, we want to gain insight into the barriers and facilitators that affect the systems' impact.

A cluster randomized controlled trial will be conducted among 120 general practices in the Netherlands. Eligible practices will be randomized to receive either the regular NHGDoc modules (control arm) or the regular modules and an additional module on heart failure (intervention arm). The effect evaluation will focus on processes of care (e.g. prescription behavior) as well as on patient outcomes (e.g. hospital admissions, mortality). Additionally, a process evaluation will be conducted, which includes a focus group study and a survey among participating healthcare providers to evaluate the perceived barriers and facilitators to using 'NHGDoc'.

Results of this study will provide insight in the ability of computerized decision support systems and in particular 'NHGDoc' to improve quality of primary care. Whereas the trial focuses on a specific NHGDoc domain - heart failure - we believe our conclusions are relevant to other primary care areas as well, particularly as this study also explores the factors that contribute to the systems' effectiveness.

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nijmegen, Netherlands, 6500 HB
        • Radboud University Nijmegen Medical Centre, IQ healthcare

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • General practices should use the information system MicroHIS X or Promedico ASP
  • NHGDoc should be available in the general practices

Exclusion Criteria:

  • General practices that do not meet the inclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Active decision support
Regular NHGDoc domains plus NHGDoc domain heart failure
Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
NO_INTERVENTION: Passive decision support
Regular NHGDoc domains

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prescribing of ACE-inhibitors/Angiotensin II
Time Frame: One year
Percentage of patients with heart failure that is prescribed ACE-inhibitors/Angiotensin II
One year
Prescribing of beta blockers
Time Frame: One year
Percentage of heart failure patients that is prescribed beta blockers
One year
Prescribing of diuretics
Time Frame: One year
Percentage of heart failure patients that is prescribed diuretics
One year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hospital admissions
Time Frame: One year
Number of hospital admissions of patients with heart failure
One year
All cause mortality
Time Frame: One year
Number of patients with heart failure that die within the hospital
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tijn Kool, PhD, IQ healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2013

Primary Completion (ACTUAL)

May 1, 2017

Study Completion (ACTUAL)

September 1, 2017

Study Registration Dates

First Submitted

November 22, 2012

First Submitted That Met QC Criteria

January 17, 2013

First Posted (ESTIMATE)

January 23, 2013

Study Record Updates

Last Update Posted (ACTUAL)

April 12, 2018

Last Update Submitted That Met QC Criteria

April 11, 2018

Last Verified

October 1, 2016

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on NHGDoc domain Heart Failure

Subscribe